CYP2D6-guided opioid therapy for adults with cancer pain : A randomized implementation clinical trial
© 2023 Pharmacotherapy Publications, Inc..
INTRODUCTION: The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer-related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6-guided opioid prescribing for patients with cancer and reported pilot outcome data.
METHODS: Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation-effectiveness clinical trial and randomized to CYP2D6-genotype-guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient-reported pain and symptom scores at baseline and up to 8 weeks, were assessed.
RESULTS: Most (87/114, 76%) patients approached for the study agreed to participate. Of 85 patients randomized, 71% were prescribed oxycodone at baseline. The median (range) time to receive CYP2D6 test results was 10 (3-37) days; 24% of patients had physicians acknowledge genotype results in a clinic note. Among patients with CYP2D6-genotype-guided recommendations to change therapy (n = 11), 18% had a change congruent with recommendations. Among patients who completed baseline and follow-up questionnaires (n = 48), there was no difference in change in mean composite pain score (-1.01 ± 2.1 vs. -0.41 ± 2.5; p = 0.19) or symptom severity at last follow-up (3.96 ± 2.18 vs. 3.47 ± 1.78; p = 0.63) between the usual care arm (n = 26) and genotype-guided arm (n = 22), respectively.
CONCLUSION: Our study revealed high acceptance of pharmacogenetic testing as part of a clinical trial among patients with cancer pain. However, provider response to genotype-guided recommendations was low, impacting assessment of pain-related outcomes. Addressing barriers to utility of pharmacogenetics results and clinical recommendations will be critical for implementation success.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 43(2023), 12 vom: 01. Dez., Seite 1286-1296 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mosley, Scott A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/phar.2875 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361957645 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361957645 | ||
| 003 | DE-627 | ||
| 005 | 20240206231916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/phar.2875 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM361957645 | ||
| 035 | |a (NLM)37698371 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mosley, Scott A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CYP2D6-guided opioid therapy for adults with cancer pain |b A randomized implementation clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Pharmacotherapy Publications, Inc. | ||
| 520 | |a INTRODUCTION: The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer-related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6-guided opioid prescribing for patients with cancer and reported pilot outcome data | ||
| 520 | |a METHODS: Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation-effectiveness clinical trial and randomized to CYP2D6-genotype-guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient-reported pain and symptom scores at baseline and up to 8 weeks, were assessed | ||
| 520 | |a RESULTS: Most (87/114, 76%) patients approached for the study agreed to participate. Of 85 patients randomized, 71% were prescribed oxycodone at baseline. The median (range) time to receive CYP2D6 test results was 10 (3-37) days; 24% of patients had physicians acknowledge genotype results in a clinic note. Among patients with CYP2D6-genotype-guided recommendations to change therapy (n = 11), 18% had a change congruent with recommendations. Among patients who completed baseline and follow-up questionnaires (n = 48), there was no difference in change in mean composite pain score (-1.01 ± 2.1 vs. -0.41 ± 2.5; p = 0.19) or symptom severity at last follow-up (3.96 ± 2.18 vs. 3.47 ± 1.78; p = 0.63) between the usual care arm (n = 26) and genotype-guided arm (n = 22), respectively | ||
| 520 | |a CONCLUSION: Our study revealed high acceptance of pharmacogenetic testing as part of a clinical trial among patients with cancer pain. However, provider response to genotype-guided recommendations was low, impacting assessment of pain-related outcomes. Addressing barriers to utility of pharmacogenetics results and clinical recommendations will be critical for implementation success | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CYP2D6 | |
| 650 | 4 | |a cancer pain | |
| 650 | 4 | |a implementation | |
| 650 | 4 | |a opioid | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2D6 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 700 | 1 | |a Cicali, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Del Cueto, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Portman, Diane G |e verfasserin |4 aut | |
| 700 | 1 | |a Donovan, Kristine A |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Langaee, Taimour |e verfasserin |4 aut | |
| 700 | 1 | |a Gopalan, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Schmit, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Starr, Jason S |e verfasserin |4 aut | |
| 700 | 1 | |a Silver, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Young D |e verfasserin |4 aut | |
| 700 | 1 | |a Rajasekhara, Sahana |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Joshua E |e verfasserin |4 aut | |
| 700 | 1 | |a Soares, Heloisa P |e verfasserin |4 aut | |
| 700 | 1 | |a Clare-Salzler, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Starostik, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a George, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a McLeod, Howard L |e verfasserin |4 aut | |
| 700 | 1 | |a Fillingim, Roger B |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, J Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallari, Larisa H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 43(2023), 12 vom: 01. Dez., Seite 1286-1296 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:1286-1296 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/phar.2875 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 12 |b 01 |c 12 |h 1286-1296 | ||